The burden of Group B *Streptococcus* worldwide for pregnant women, stillbirths and children

Paper 5: Preterm birth associated with Group B Streptococcus maternal colonization worldwide: systematic review and meta-analyses

**Supplementary information** 

#### **Contents**

|   | he burden of Group B <i>Streptococcus</i> worldwide for pregnant women, stillbirths and hildren1  |
|---|---|
|   | Paper 5: Preterm birth associated with Group B Streptococcus maternal colonization vorldwide: systematic review and meta-analyses1  |
| S | Supplementary information1  |
|   | Supplementary Table S1: search terms3   |
|   | Supplementary Table S2: inclusion and exclusion criteria5   |
|   | Supplementary Table S3: Study characteristics and data6   |
|   | Supplementary Figure S1: Meta-analysis of cohort studies with GBS colonization detected from urine samples by time of sampling  |
|   | Supplementary Figure S2: Meta-analysis of case control studies with GBS colonization detected from urine samples20  |
|   | Supplementary Figure S3: Meta-analysis of cohort and cross sectional studies for studies using recto-vaginal sampling and broth selective enrichment for isolation of GBS by time of sampling                                 |
|   | Supplementary Figure S4: Meta-analysis of case-control studies for studies using rectovaginal sampling and broth selective enrichment for isolation of GBS22  |
|   | Supplementary Figure S5: Meta-analysis of cohort and cross sectional studies using nonselective laboratory methods and cervical and upper vaginal sampling by time of sampling  |
|   | Supplementary Figure S6: Meta-analysis of case-control studies using nonselective laboratory methods and cervical and upper vaginal sampling24  |
|   | Supplementary Figure S7: Meta-analysis of cohort and cross sectional studies where mothers reported not using antibiotics (AB) during pregnancy or at least one week before the culture sample was taken, by time of sampling |
|   | Supplementary Figure S8: Meta-analysis of case-control studies where mothers reported not using antibiotics (AB) during pregnancy or at least one week before the culture sample was taken                                    |
|   | Supplementary Figure S9: Meta-analysis of cohort and cross sectional studies for studies measuring GA by LMP, ultrasound and/or fundal height   |
|   | Supplementary Figure S10: Meta-analysis of case-control studies for studies for studies measuring GA by LMP, ultrasound and/or fundal height  |
|   | Supplementary Figure S11: Meta-analysis without cohort and cross-sectional studies using different thresholds for the definition of preterm (or not specifying the definition) by time of sampling                            |
|   | Supplementary Figure 12: Meta-analysis without case-control studies using different thresholds for the definition of preterm (or not specifying the definition)30   |

#### Supplementary Table S1: search terms

("infant, premature"[MeSH Terms] OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields] OR "prematurity"[All Fields]) OR ("infant, premature"[MeSH Terms] OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields] OR ("prematurity"[All Fields] AND "infant"[All Fields])) OR (premature [All Fields] AND ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND "newborn"[All Fields]) OR "newborn infant" [All Fields] OR "neonate"[All Fields])) OR ("infant, premature"[MeSH Terms] OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields]) OR ("premature"[All Fields]) OR ("premature birth"[MeSH Terms] OR ("premature"[All Fields]) OR "premature birth"[All Fields]) OR "premature birth"[All Fields]) OR "premature birth"[All Fields]) OR ("premature"[All Fields]) OR ("premature"[All Fields]) OR ("premature"[All Fields]) OR ("premature"[All Fields]) OR ("premature[All Fields]) OR ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields]) AND "newborn"[All Fields]) OR "newborn infant"[All Fields] OR "newborn"[All Fields]))

OR prematuritas[All Fields] OR ("premature labour"[All Fields] OR "obstetric labor, premature"[MeSH Terms] OR ("obstetric"[All Fields] AND "labor"[All Fields] AND "premature"[All Fields]) OR "premature obstetric labor"[All Fields] OR ("premature"[All Fields]) AND "labor"[All Fields]) OR ("obstetric labor, premature"[MeSH Terms] OR ("obstetric"[All Fields] AND "labor"[All Fields] AND "premature"[All Fields]) OR "premature obstetric labor"[All Fields] OR ("labor"[All Fields]) AND "premature"[All Fields]) OR "labor, premature"[All Fields]) OR ("obstetric labor, premature"[All Fields]) OR ("obstetric labor, premature"[All Fields]) OR "premature obstetric labor"[All Fields] OR ("labor"[All Fields]) OR "premature"[All Fields]) OR "premature obstetric labor, premature"[All Fields]) OR "obstetric labor, premature"[All Fields])

OR ("premature birth"[MeSH Terms] OR ("premature"[All Fields] AND "birth"[All Fields]) OR "premature birth"[All Fields] OR ("premature"[All Fields] AND "delivery"[All Fields]) OR "premature delivery"[All Fields]) OR ("infant, premature"[MeSH Terms] OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields] OR ("premature"[All Fields]) OR ("infant, premature"[MeSH Terms] OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields]) OR "preterm"[All Fields] AND "infant"[All Fields]) OR "preterm infant"[All Fields]) OR ("premature birth"[MeSH Terms] OR ("preterm"[All Fields] AND "birth"[All Fields]) OR "premature birth"[All Fields] OR ("preterm"[All Fields] AND "delivery"[All Fields]) OR "preterm delivery"[All Fields])

OR ("obstetric labor, premature" [MeSH Terms] OR ("obstetric" [All Fields] AND "labor" [All Fields] AND "premature" [All Fields]) OR "premature obstetric labor" [All Fields] OR ("preterm" [All Fields] AND "labor" [All Fields]) OR "preterm labor" [All Fields]) OR (preterm [All Fields]) OR (preterm [All Fields]) OR ("infant, newborn" [MeSH Terms]) OR ("infant" [All Fields]) OR ("premature birth" [MeSH Terms]) OR ("premature" [All Fields]) OR "premature birth" [All Fields]) OR ("preterm" [All Fields]) OR "preterm birth" [All Fields]) OR ("preterm" [All Fields]) OR ("infant, premature" [MeSH Terms]) OR ("infant" [All Fields]) OR "preterm baby" [All Fields]) OR ("preterm [All Fields]) OR ("preterm baby" [All Fields]) OR (preterm [All Fields]) OR ("infant" [MeSH Terms]) OR "infant" [All Fields]) OR ("preterm [All Fields]) OR ("infant, newborn" [MeSH Terms]) OR ("infant" [All Fields]) OR "newborn" [MeSH Terms]) OR ("infant" [All Fields]) OR "newborn" [All Fields]) OR "newborn" [All Fields]) OR "newborn" [All Fields])

infant"[All Fields] OR "baby"[All Fields] OR "infant"[MeSH Terms] OR "infant"[All Fields])) OR (pre-term[All Fields] AND ("parturition"[MeSH Terms] OR "parturition"[All Fields] OR "birth"[All Fields])) OR (pre-term[All Fields] AND ("infant"[MeSH Terms] OR "infant"[All Fields] OR "babies"[All Fields])) OR (pre-mature[All Fields] AND ("delivery, obstetric"[MeSH Terms] OR ("delivery"[All Fields] AND "obstetric"[All Fields]) OR "obstetric delivery"[All Fields] OR "delivery"[All Fields])) OR (pre-mature[All Fields] AND ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND "newborn"[All Fields])) OR "newborn infant"[All Fields] OR "baby"[All Fields] OR "infant"[MeSH Terms] OR "infant"[All Fields]))

(Taken from Blencowe et al. 2012)

#### **AND**

("Streptococcus" [All Fields] OR "Streptococcal" [All Fields] OR "Streptococci" [All Fields]) AND (("Group" AND "B") or "Agalactiae") OR "Streptococcus Agalactiae" [MeSH Terms]

Limit: humans

#### Supplementary Table S2: inclusion and exclusion criteria

|                        | Inclusion criteria  | Exclusion criteria   |
|------------------------|---|--|
| Population             | Number of preterm and term births in both GBS and non-GBS carriers                        | Non appropriate comparison group   |
| Laboratory/definitions | Recto-vaginal swab (or rectal or vaginal), vaginal, cervical Urine, chorioamnion or mixed | Preterm labor not properly defined   |
| Search                 | No language limits No date limits   | Conference abstracts where it was not possible to obtain further information |

Supplementary Table S3: Study characteristics and data

| Study    | Year of publication | Country |                               | Time of screening  | Definition of outcome (preterm birth/labor)  | Site of<br>sample<br>taken                 | Lab<br>methods  | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics     | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|----------|---------------------|---------|-------------------------------|--|--|--|---|--|--|----------------|---------------------------------|-------------------------------|
| Aali     | 2007                | Iran    | Case-<br>control              | labor/delive<br>ry   | Four uterine contractions in 20 minutes time period with cervical dilatation >1cm and cervical effacement of ≥80% before 37 weeks' gestation | vaginal                                    | blood and<br>chocolate<br>agar plates                               | date of last<br>menstrual<br>period or<br>ultrasonogra<br>phic report in<br>the first half<br>of pregnancy | women in<br>current<br>antibiotic<br>usage | 206            | 1.89                            | 0.71-5.01                     |
| Agger    | 2014                | USA     | Cohort                        | 11.5 (± 3.7)<br>weeks'<br>gestation                                | delivery <37<br>weeks'<br>gestation  | cervical                                   | not specified   |  |  | 676            | 0.37                            | 0.15-0.90                     |
| Allen    | 1999                | Canada  | Cohort<br>(retrosp<br>ective) | early third<br>trimester<br>(26-28<br>weeks<br>gestational<br>age) | delivery <37<br>weeks'<br>gestation  | vaginal<br>or<br>vaginal-<br>anorect<br>al | GBS broth<br>(Lim<br>broth/selectiv<br>e media)                     |  |  | 986            | 2.10                            | 1.38-3.20                     |
| Anderson | 2007                | USA     | Cohort<br>(retrosp<br>ective) | before 20<br>week's<br>gestation                                   | delivery <37<br>weeks'<br>gestation  | urine<br>cultures                          | sheep blood<br>agar,<br>macconkey<br>agar and<br>GBS agar<br>plates |  |  | 243            | 1.79                            | 1.01-3.17                     |
| Choi     | 2012                | Korea   | Case-<br>control              | at delivery  | not specified  | vaginal,<br>anorect<br>um, and<br>urethral | Todd-Hewitt<br>broth and<br>new Granada<br>plate                    |  |  | 160            | 0.45                            | 0.16-1.21                     |

| Study       | Year of publication | Country | Study<br>design               | Time of screening                | Definition of outcome (preterm birth/labor)                                       | Site of sample taken orifice swabs                               | Lab<br>methods   | Gestational<br>age<br>measured  | Exclusion<br>of women<br>who had<br>antibiotics   | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-------------|---------------------|---------|-------------------------------|----------------------------------|---|--|--|---|---|----------------|---------------------------------|-------------------------------|
| Citernesi   | 1996                | Italy   | Cross-<br>sectiona            | at delivery                      | delivery <37<br>weeks'<br>gestation   | vaginal  | blood agar<br>plates   |   |   | 4672           | 1.33                            | 0.83-2.13                     |
| Dahan-Saal  | 2011                | France  | Cohort<br>(retrosp<br>ective) | not<br>specified                 | delivery <37<br>weeks'<br>gestation   | vaginal<br>(positive<br>women<br>also<br>urine<br>and<br>newborn | Polyvitex1<br>and gels to<br>ANC                                 |   |   | 8733           | 1.13                            | 0.98-1.30                     |
| Daskalakis  | 2006                | Greece  | Cohort                        | 22 and 25<br>weeks'<br>gestation | delivery <37<br>weeks'<br>gestation   | vaginal  | blood agar<br>plates with<br>gentamicin<br>and nalidixic<br>acid | date of last<br>menstrual<br>period or a<br>1st trimester<br>scan if there<br>was a<br>discrepancy<br>of more than<br>a weeks | women who received an antibiotic effective against BV or GBS at any gestational age following the screening | 1197           | 0.43                            | 0.19-0.96                     |
| Discacciati | 2011                | Brazil  | Case-<br>control              | at labor                         | One uterine contraction every 5-8 minutes with cervical dilatation of >2cm and/or | vaginal  | blood agar<br>plates   |   | women who used antibiotics during the two preceding weeks   | 82             | 5.33                            | 0.57-49.97                    |

| Study                 | Year of publication | Country     | Study<br>design | Time of screening                            | Definition of outcome (preterm birth/labor)            | Site of<br>sample<br>taken | Lab<br>methods       | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-----------------------|---------------------|-------------|-----------------|--|--|----------------------------|----------------------|--|--|----------------|---------------------------------|-------------------------------|
|                       |                     |             |                 |  | cervical effacement of ≥50% before 37 weeks' gestation |                            |                      |  |  |                |                                 |                               |
| Feikin                | 2001                | Denmar<br>k | Cohort          | at<br>enrollment<br>≤ 24 weeks'<br>gestation | delivery <37<br>weeks'<br>gestation                    | cervical<br>and<br>vaginal | blood agar<br>plates | date of the last menstrual period and ultrasonogra phic measuremen ts at 18 weeks gestation were used to confirm gestational age |  | 2846           | 0.97                            | 0.47-1.98                     |
| Feikin<br>(continued) | 2001                | Denmar<br>k | Cohort          | at delivery                                  | delivery <37<br>weeks'<br>gestation                    | cervical<br>and<br>vaginal | blood agar<br>plates | date of the last menstrual period and ultrasonogra phic measuremen ts at 18 weeks gestation were used to confirm gestational age |  | 384            | 1.72                            | 1.04-2.83                     |

| Study                 | Year of publication | Country                         | Study<br>design               | Time of screening   | Definition of outcome (preterm birth/labor)           | Site of<br>sample<br>taken            | Lab<br>methods  | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-----------------------|---------------------|---------------------------------|-------------------------------|---|---|---------------------------------------|---|--|--|----------------|---------------------------------|-------------------------------|
| Feikin<br>(continued) | 2001                | Denmar<br>k                     | Case-<br>control              | Controls had specimens taken during routine visits in prenatal clinic; cases specimens taken during labor | delivery <37<br>weeks'<br>gestation                   | cervical<br>and<br>vaginal            | blood agar<br>plates  | date of the last menstrual period and ultrasonogra phic measuremen ts at 18 weeks gestation were used to confirm gestational age |  | 308            | 1.91                            | 0.88-4.15                     |
| Garland               | 2000                | Australi<br>a                   | Cohort<br>(retrosp<br>ective) | at week 28<br>or 32 of<br>gestation   | delivery <37<br>weeks'<br>gestation                   | vaginal                               | Todd-Hewitt<br>broth with<br>crystal violet,<br>colistin, and<br>nalidixic acid | Both by<br>ultrasound<br>and by dates  |  | 1120           | 0.53                            | 0.37-0.75                     |
| Gerards               | 1982                | Netherla<br>nds                 | Cohort                        | before 20th<br>week, at<br>28th and<br>34th week's<br>gestation<br>and at<br>delivery                     | not specified   | vaginal,<br>cervical<br>and<br>rectal | sheep blood<br>agar plate<br>and selective<br>broth<br>medium of<br>Pike        |  |  | 161            | 0.62                            | 0.26-1.50                     |
| Gojnic                | 2005                | Serbia<br>and<br>Monten<br>egro | Case-<br>control              | at delivery   | delivery<br>between 24<br>to 37 weeks<br>of gestation | cervical                              | not specified   |  |  | 232            | 2.43                            | 0.44-13.54                    |

| Study           | Year of publication | Country | Study<br>design         | Time of screening  | Definition of outcome (preterm birth/labor) | Site of<br>sample<br>taken   | Lab<br>methods  | Gestational<br>age<br>measured  | Exclusion of women who had antibiotics                              | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-----------------|---------------------|---------|-------------------------|--|---|--|---|---|---|----------------|---------------------------------|-------------------------------|
| Hakansson       | 2008                | Sweden  | Cross-<br>sectiona<br>I | at delivery  | delivery <37<br>weeks'<br>gestation         | vaginal<br>and<br>rectal   | Todd-Hewitt with nalidixic acid and gentamicin  |   |   | 1507           | 0.63                            | 0.37-1.07                     |
| Hassanzad<br>eh | 2011                | Iran    | Cross-<br>sectiona      | at delivery  | delivery <37<br>weeks'<br>gestation         | vaginal-<br>rectal   | Todd-Hewitt<br>broth with<br>gentamicin<br>and nalidixic<br>acid  |   |   | 310            | 1.55                            | 0.34-7.07                     |
| Hastings        | 1986                | UK      | Cohort                  | at booking,<br>28 and 36<br>weeks'<br>gestation<br>and during<br>labor | delivery <37<br>weeks'<br>gestation         | vaginal<br>and<br>rectal   | blood agar<br>and Islam's<br>starch serum<br>agar with<br>with nalidixic<br>acid and<br>gentamicin<br>sulphate,<br>Todd Hewitt<br>broth |   |   | 1059           | 1.01                            | 0.60-1.68                     |
| Hillier         | 1991                | USA     | Case-<br>control        | at delivery  | delivery at<br>≤34<br>completed<br>weeks    | chorioa<br>mnion<br>cultures<br>and<br>placenta<br>histologi<br>c<br>samples | not specified   | date of last<br>menstrual<br>period,<br>fundal<br>height,<br>ultrasonogra<br>phy and an<br>evaluation of<br>the newborn<br>with a<br>standardized<br>Ballard<br>examination | women who<br>had received<br>antibiotics in<br>the previous<br>week | 268            | 3.92                            | 1.02-15.13                    |

| Study                  | Year of publication | Country     | Study<br>design               | Time of screening                   | Definition of outcome (preterm birth/labor)       | Site of<br>sample<br>taken | Lab<br>methods  | Gestational<br>age<br>measured | Exclusion of women who had antibiotics | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|------------------------|---------------------|-------------|-------------------------------|-------------------------------------|---|----------------------------|---|--------------------------------|--|----------------|---------------------------------|-------------------------------|
| Jones                  | 2006                | UK          | Cohort                        | between 34<br>weeks to<br>full term | delivery <37<br>weeks'<br>gestation               | vaginal-<br>rectal         | Todd-Hewitt broth with gentamicin and nalidixic acid and NNA plate with neomycin and nalidixic acid |                                |  | 167            | 0.00                            |                               |
| Joshi                  | 1987                | Canada      | Cross-<br>sectiona<br>I       | at delivery                         | delivery at or<br>before 37<br>weeks<br>gestation | vaginal                    | blood agar<br>plates  |                                |  | 3078           | 2.49                            | 1.62-3.83                     |
| Kessous                | 2012                | Israel      | Cohort<br>(retrosp<br>ective) | not<br>specified                    | delivery <37<br>weeks'<br>gestation               | vaginal                    | not specified   |                                |  | 216132         | 0.76                            | 0.66-0.88                     |
| Kessous(co<br>ntinued) | 2012                | Israel      | Cohort<br>(retrosp<br>ective) | not<br>specified                    | delivery <37<br>weeks'<br>gestation               | urine<br>cultures          | not specified   |                                |  | 215393         | 1.94                            | 1.76-2.14                     |
| Khalil                 | 2015                | Denmar<br>k | Cohort<br>(retrosp<br>ective) | during<br>pregnancy                 | not specified                                     | urine<br>cultures          | not specified   |                                |  | 13417          | 1.66                            | 1.41-1.97                     |
| Kim                    | 2015                | Korea       | Cohort                        | last<br>trimester                   | not specified                                     | vaginal<br>and<br>rectal   | Todd-Hewitt<br>broth and<br>CHROMagar<br>StrepB agar<br>(CHROM-B)                                   |                                |  | 107            | 1.38                            | 0.77-2.45                     |

| Study    | Year of publication | Country  | Study<br>design  | Time of screening  | Definition of outcome (preterm birth/labor)  | Site of<br>sample<br>taken            | Lab<br>methods  | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics                       | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|----------|---------------------|----------|------------------|--|--|---------------------------------------|---|--|--|----------------|---------------------------------|-------------------------------|
| Kovachev | 2003                | Bulgaria | Cohort           | 24 weeks'<br>gestation   | not specified  | cervical<br>and<br>vaginal            | blood agar<br>with<br>gentamicin<br>and nalidixic   |  | women who used antibiotics therapy within the past two weeks | 110            | 10.22                           | 2.81-37.16                    |
| Lamont   | 1986                | UK       | Case-<br>control | at admission for preterm labor or 24 h before elective delivery (controls) | At least two uterine contractions in 10 minutes (gestation weeks not specified)                            | cervical,<br>vaginal<br>and<br>rectal | neomycin blood agar and enrichment medium with gentamicin and nalidixic acid                |  |  | 98             | 0.00                            |                               |
| LeDoare  | unpublished<br>data | Gambia   | Cohort           | at delivery  | delivery <37<br>weeks'<br>gestation  | vaginal-<br>rectal                    | Todd-Hewitt<br>enrichment<br>and agar<br>plating<br>CCNA                                    | Ballard score  |  | 750            | 1.07                            | 0.88-1.29                     |
| Martius  | 1988                | USA      | Case-<br>control | at delivery  | Two or more uterine contractions within 10 minutes, lasting longer than 2 hours before 37 weeks' gestation | vaginal<br>and<br>cervical            | sheep blood<br>agar and<br>Todd-Hewitt<br>broth with<br>gentamicin<br>and naladixic<br>acid | date of last<br>menstrual<br>period,<br>fundal<br>height, and<br>ultrasonogra<br>phy when<br>available | women who<br>used within<br>two weeks of<br>enrollment       | 212            | 1.82                            | 0.84-3.97                     |

| Study     | Year of publication | Country  | Study<br>design  | Time of screening  | Definition of outcome (preterm birth/labor)      | Site of<br>sample<br>taken | Lab<br>methods   | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics                           | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-----------|---------------------|----------|------------------|--|--|----------------------------|--|--|--|----------------|---------------------------------|-------------------------------|
| Matorras  | 1989                | Spain    | Cohort           | samples<br>from range<br>of 17th to<br>42nd<br>weeks'<br>gestation | delivery <37<br>completed<br>weeks'<br>gestation | vaginal<br>and<br>rectal   | blood agar<br>with nalidixic<br>acid and<br>Todd-Hewitt<br>broth with<br>blood and<br>nalidixic acid | date of last<br>menstrual<br>period  |  | 1011           | 0.91                            | 0.58-1.43                     |
| Mc Kenzie | 1994                | UK       | Cohort           | 28 weeks   | delivery <37<br>weeks'<br>gestation              | urine<br>samples           | blood agar<br>plates   | Menstrual data and corrected if early ultrasound showed a discrepancy of greater than one week |  | 1866           | 0.31                            | 0.04-2.16                     |
| Mikhova   | 2007                | Bulgaria | Case-<br>control | not<br>specified   | delivery <34<br>weeks                            | vaginal                    | not specified  |  | women who had antibiotic treatment previous to the sample taking | 88             | 3.29                            | 0.60-17.95                    |

| Study    | Year of publication | Country     | Study<br>design               | Time of screening   | Definition of outcome (preterm birth/labor)  | Site of<br>sample<br>taken                          | Lab<br>methods   | Gestational<br>age<br>measured | Exclusion of women who had antibiotics                                       | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|----------|---------------------|-------------|-------------------------------|---|--|---|--|--------------------------------|--|----------------|---------------------------------|-------------------------------|
| Minkoff  | 1984                | USA         | Cohort                        | first<br>prenatal<br>visit (13.8<br>+/- 3.6<br>weeks'<br>gestation) | More than one contraction every 8 minutes and cervical effacement >75% or >1cm dilatation before 37 weeks' gestation | vaginal   | modified Thayer- Martin agar, chocolate agar, tryptic soy agar containing sheep blood, MacConkey agar, and bile esculin azide agar |                                | women were<br>not given<br>antibiotics<br>after cultures<br>were<br>obtained | 218            | 1.84                            | 0.86-3.94                     |
| Moller   | 1984                | Denmar<br>k | Cohort                        | at least<br>once<br>between 12<br>and 38<br>weeks'<br>gestation     | delivery<br>before the<br>end of week<br>37 of<br>gestation  | urine<br>samples                                    | not specified  |                                |  | 2745           | 2.52                            | 1.55-4.08                     |
| Persson  | 1986                | Sweden      | Case-<br>control              | at delivery   | delivery <37<br>weeks'<br>gestation  | urethral,<br>rectal<br>and<br>urine                 | Todd-Hewitt<br>broth with<br>gentamicin<br>and nalidixic<br>acid   |                                |  | 366            | 1.21                            | 0.49-2.99                     |
| Petersen | 2014                | Denmar<br>k | Cohort<br>(retrosp<br>ective) | during<br>pregnancy   | delivery <37<br>weeks'<br>gestation  | urine<br>samples<br>and<br>lower<br>vagina<br>swabs | blood agar<br>resistance<br>plate and a<br>chromID<br>CPS plate<br>specific for<br>GBS   |                                |  | 35175          | 1.81                            | 1.57-2.10                     |


| Study  | Year of publication | Country       | Study<br>design | Time of screening                   | Definition of outcome (preterm birth/labor)      | Site of<br>sample<br>taken           | Lab<br>methods  | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics   | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|--------|---------------------|---------------|-----------------|-------------------------------------|--|--------------------------------------|---|--|--|----------------|---------------------------------|-------------------------------|
| Regan  | 1981                | USA           | Cohort          | at delivery                         | delivery <32<br>weeks'<br>gestation              | cervical                             | not specified   | date of last<br>menstrual<br>period, when<br>in doubt<br>Usher score<br>of physical<br>examination<br>criteria of the<br>infant during<br>first 24 hours<br>of life                |  | 6706           | 4.11                            | 2.88-5.87                     |
| Regan  | 1996                | USA           | Cohort          | at 23 to 26<br>weeks'<br>gestation  | delivery <37<br>completed<br>weeks'<br>gestation | vaginal,<br>endocer<br>vical<br>swab | selective<br>broth media<br>containing<br>gentamicin<br>and nalidixic<br>acid | date of last<br>menstrual<br>period, and<br>other clinical<br>evidence<br>such as<br>uterine size,<br>detection of<br>fetal heart<br>tones and<br>ultrasonogra<br>phy when<br>done | results for<br>women who<br>were not<br>administered<br>effective<br>antibiotics | 10385          | 1.04                            | 0.91-1.20                     |
| Schwab | 2016                | Indonesi<br>a | Cohort          | second<br>trimester of<br>pregnancy | delivery <37<br>weeks'<br>gestation              | vaginal<br>swabs                     | not specified   | Self-reported<br>last<br>menstrual<br>period   |  | 62             | 2.22                            | 1.24-3.98                     |

| Study  | Year of publication | Country     | Study<br>design    | Time of screening                           | Definition of outcome (preterm birth/labor)   | Site of<br>sample<br>taken | Lab<br>methods  | Gestational<br>age<br>measured   | Exclusion of women who had antibiotics                               | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|--------|---------------------|-------------|--------------------|---|---|----------------------------|---|--|--|----------------|---------------------------------|-------------------------------|
| Seale  | 2016                | Kenya       | Cohort             | at delivery                                 | delivery ≥32<br><37 weeks'<br>gestation   | recto-<br>vaginal<br>swabs | Amies transport medium with charcoal, enrichment Lim broth and subculture onto blood agar | last<br>menstrual<br>period when<br>available<br>(fundal<br>height if not) |  | 7408           | 0.89                            | 0.80-0.99                     |
| Seoud  | 2010                | Lebano<br>n | Cross-<br>sectiona | at delivery                                 | delivery ≤36<br>weeks'<br>gestation   | vaginal<br>and<br>rectal   | SBA plate   |  |  | 774            | 0.93                            | 0.51-1.68                     |
| Seyyed | 2013                | Iran        | Case-<br>control   | at<br>admission<br>to hospital<br>for labor | Four in 20 minutes or eight in 60 minutes uterine contractions and progressive change in cervix or ≥80% cervical effacement between 20- 37 weeks' gestation | vaginal<br>and<br>rectal   | Todd-Hewitt<br>broth with<br>gentamicin<br>and nalidixic<br>acid                          |  | women who<br>used<br>antibiotics<br>during two<br>preceding<br>weeks | 329            | 2.53                            | 1.55-4.13                     |


| Study   | Year of publication | Country      | Study<br>design | Time of screening  | Definition of outcome (preterm birth/labor)          | Site of<br>sample<br>taken | Lab<br>methods   | Gestational<br>age<br>measured | Exclusion of women who had antibiotics   | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|---------|---------------------|--------------|-----------------|--|--|----------------------------|--|--------------------------------|--|----------------|---------------------------------|-------------------------------|
| Sweet   | 1987                | USA          | Cohort          | initial prenatal visit and repeated at 30 to 34 weeks' gestation | not specified  | vaginal                    | trypicase soy<br>agar plate<br>with sheep<br>blood (TSB)<br>and NPC<br>broth |                                |  | 3028           | 1.2                             | 0.83-1.74                     |
| Thomsen | 1987                | Denmar<br>k  | Cohort          | between 27<br>and 31<br>weeks'<br>gestation                      | delivery<br>before end of<br>week 37 of<br>gestation | urine<br>cultures          | not specified  |                                | women in a<br>trial, results<br>for GBS<br>positive<br>women<br>given<br>placebo | 4085           | 7.98                            | 5.00-12.74                    |
| Tsolia  | 2003                | Greece       | Cohort          | during<br>follow-up<br>exam (≥ 35<br>weeks) or<br>at labor       | delivery <37<br>weeks'<br>gestation                  | vaginal<br>and<br>rectal   | Todd-Hewitt broth with gentamicin and nalidixic acid                         |                                |  | 1014           | 1.17                            | 0.54-2.54                     |
| Tsui    | 2002                | Hong<br>Kong | Cohort          | at first or<br>second<br>trimester                               | delivery ≤ 37<br>weeks'<br>gestation                 | vaginal<br>and<br>rectal   | Todd-Hewitt broth with gentamicin and nalidixic acid                         |                                |  | 952            | 1.09                            | 0.48-2.48                     |
| White   | 1984                | UK           | Cohort          | antenatal  | labor <37<br>weeks'<br>gestation                     | urine<br>cultures          | not specified  |                                |  | 8083           | 1.49                            | 0.81-2.73                     |

| Study | Year of publication | Country | Study<br>design         | Time of screening | Definition of outcome (preterm birth/labor)   | Site of<br>sample<br>taken | Lab<br>methods   | Gestational<br>age<br>measured | Exclusion of women who had antibiotics | Sample<br>size | Risk<br>ratio/<br>Odds<br>ratio | 95%<br>confidence<br>interval |
|-------|---------------------|---------|-------------------------|-------------------|---|----------------------------|--|--------------------------------|--|----------------|---------------------------------|-------------------------------|
| Wilk  | 2003                | Poland  | Cross-<br>sectiona<br>I | at delivery       | delivery<br>before the<br>end of 37th<br>week | cervical                   | sheep blood<br>agar,<br>MacConkey<br>agar and<br>Chapman<br>agar, brain<br>heart infusion<br>broth |                                |  | 656            | 1.85                            | 1.01-3.14                     |


#### Supplementary Figure S1: Meta-analysis of cohort studies with GBS colonization detected from urine samples by time of sampling.




#### Supplementary Figure S2: Meta-analysis of case control studies with GBS colonization detected from urine samples.




#### Supplementary Figure S3: Meta-analysis of cohort and cross sectional studies for studies using recto-vaginal sampling and broth selective enrichment for isolation of GBS by time of sampling




## Supplementary Figure S4: Meta-analysis of case-control studies for studies using recto-vaginal sampling and broth selective enrichment for isolation of GBS




## Supplementary Figure S5: Meta-analysis of cohort and cross sectional studies using nonselective laboratory methods and cervical and upper vaginal sampling by time of sampling



# Supplementary Figure S6: Meta-analysis of case-control studies using nonselective laboratory methods and cervical and upper vaginal sampling




Supplementary Figure S7: Meta-analysis of cohort and cross sectional studies where mothers reported not using antibiotics (AB) during pregnancy or at least one week before the culture sample was taken, by time of sampling




Supplementary Figure S8: Meta-analysis of case-control studies where mothers reported not using antibiotics (AB) during pregnancy or at least one week before the culture sample was taken

|                  |               | Year            |             |             |   |            |                    | %      |
|------------------|---------------|-----------------|-------------|-------------|---|------------|--------------------|--------|
| Region           | Country       | published       | Author      | Sample_size |   |            | OR (95% CI)        | Weight |
|                  |               |                 |             |             |   |            |                    |        |
| Asia             | Iran          | 2007            | Aali        | 206         |   | *          | 1.89 (0.71, 5.01)  | 14.14  |
| Developed        | USA           | 1988            | Martius     | 212         |   |            | 1.79 (0.83, 3.87)  | 22.60  |
| Developed        | Bulgaria      | 2007            | Mikhova     | 88          |   |            | 3.29 (0.60, 17.95) | 4.67   |
| Developed        | Iran          | 2013            | Seyyed      | 329         |   | -          | 2.53 (1.55, 4.13)  | 55.90  |
| Latin America    | Brazil        | 2011            | Discacciati | 82          | - | •          | 5.33 (0.57, 49.96) | 2.69   |
| Overall (I-squar | ed = 0.0%, p  | = 0.840)        |             |             |   | $\Diamond$ | 2.32 (1.61, 3.34)  | 100.00 |
| NOTE: Weights    | are from rand | dom effects ana | ılysis      |             |   |            |                    |        |
|                  |               |                 |             | .02         |   | 1          | T<br>50            |        |


## Supplementary Figure S9: Meta-analysis of cohort and cross sectional studies for studies measuring GA by LMP, ultrasound and/or fundal height



# Supplementary Figure S10: Meta-analysis of case-control studies for studies for studies measuring GA by LMP, ultrasound and/or fundal height



## Supplementary Figure S11: Meta-analysis without cohort and cross-sectional studies using different thresholds for the definition of preterm (or not specifying the definition) by time of sampling



# Supplementary Figure 12: Meta-analysis without case-control studies using different thresholds for the definition of preterm (or not specifying the definition)

